Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feucht, H.-H.
Right arrow Articles by Laufs, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feucht, H.-H.
Right arrow Articles by Laufs, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, Vol. 89 No. 6 (March 15), 1997: pp. 2223-2223

CORRESPONDENCE

GB Virus C Infection and Liver Transplantation: Increased Risk of Transfusion-Transmitted Infection

    LETTER

To the Editor:

GB virus C (GBV-C) and hepatitis G virus (HGV) are recently discovered RNA viruses that infect humans. Because GBV-C and HGV are most likely isolates of the same virus, the GBV-C nomenclature will be used throughout this letter. GBV-C seems to cause hepatitis unrelated to infection with hepatitis A, B, C, D, or E viruses.1 It has been reported that GBV-C infection may be linked to fulminant hepatitis.2,3 Therefore, in a retrospective study, we investigated 109 patients (41 women and 68 men; median age, 49 years) who underwent liver transplantation between 1992 and 1996. Seventeen (15.6%) of them had a history of fulminant hepatitis, 11 of unknown etiology, 5 of hepatitis B virus (HBV) infection, and 1 of hepatitis A virus (HAV) infection. The other 92 (84.4%) patients had liver cirrhosis due to autoimmune hepatitis (27 [24.8%]), chronic hepatitis C virus (HCV) infection (27 [24.8%]), chronic HBV infection (11 [10.1%]), HBV and hepatitis D virus (HDV) infection (4 [3.7%]), alcohol abuse (15 [13.8%]), unknown etiology (6 [5.5%]), or other (2 [1.8%]). GBV-C infection was investigated by reverse transcription-polymerase chain reaction (RT-PCR) using primers of the helicase-like region. At the time of liver transplantation, 7 (6.4%) of the 109 patients had detectable GBV-C viremia. Of these 7 patients, 4 patients had liver cirrhosis due to alcohol abuse, 2 patients had autoimmune hepatitis, and 1 patient had a cryptogenic cirrhosis. None of the 17 patients with fulminant hepatitis had detectable GBV-C viremia before or at the time of transplantation. Postoperatively, the 7 GBV-C-infected patients and additionally 42 patients (38.5%) had detectable viremia in sera drawn between days 6 and 14 after transplantation. These 49 patients showed a persistent GBV-C viremia during follow-up between 5 months and 4 years. The other 60 patients remained negative in GBV-C PCR.

One important route of GBV-C transmission is blood products (blood plasma and erythrocyte and thrombocyte concentrates).4 Therefore, we examined the number of blood products administered to these patients in connection with liver transplantation. We did not find a significant difference between the number of blood products administered to the 42 patients who acquired GBV-C infection perioperatively (median, 142 U) and the 60 patients without GBV-C infection (median, 137.5 U).

From our results we conclude that GBV-C infection is not linked to fulminant hepatitis. Our data further show that patients who undergo liver transplantation are at high risk for acquiring GBV-C infection. The prevalence after transplantation was 41.2%, in contrast to 6.4% before transplantation. Transfusion-transmitted GBV-C infection has to be assumed due to the great number (median, 140 U) required for liver transplantation. This is in agreement with previously published data in patients with hematologic malignancy.5 Clinical studies are already in progress to evaluate the clinical impact of GBV-C infection in liver transplant recipients.

Heinz-Hubert Feucht
Lutz Fischer
Martina Sterneck
Bärbel Knödler
Christoph-E. Broelsch
Rainer Laufs
Institute of Medical Microbiology and Immunology Department of General Surgery Department of Internal Medicine Department of Transfusion Medicine Universitätskrankenhaus Eppendorf Hamburg, Germany

  

    REFERENCES

1. Simons JN, Leary TP, Dawson GJ, Pilot-Matias TJ, Dawson GJ, Erker JC Chalmers ML, Schlauder GG, Desai SM, Mushawar IK: Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1:564, 1995[Medline] [Order article via Infotrieve]

2. Yoshiba M, Okamoto H, Mishiro S: Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown aetiology. Lancet 346:1131, 1995[Medline] [Order article via Infotrieve]

3. Kao JH, Chen PJ, Chen DS: GBV-C in the aetiology of fulminant hepatitis. Lancet 347:120, 1996[Medline] [Order article via Infotrieve]

4. Wang JT, Tsai FC, Lee CZ, Chen PJ, Sheu JC, Wang TH, Chen DS: A prospective study of transfusion-transmitted GB virus C infection: Similar frequency but different clinical presentation compared with hepatitis C virus. Blood 88:1881, 1996[Abstract/Free Full Text]

5. Neilson J, Harrison P, Milligan DW, Skidmore SJ, Collingham KE: Hepatitis G virus long-term survivors of haematological malignancy. Lancet 347:1632, 1996[Medline] [Order article via Infotrieve]


© 1997 by The American Society of Hematology.

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
M. Schroter, R. Laufs, M. Sterneck, L. Fischer, B. Knodler, P. Schafer, B. Zollner, and H.-H. Feucht
SENV-H viremia and liver transplantation: significant increase of the prevalence
Blood, July 30, 2002; 100(4): 1518 - 1519.
[Full Text] [PDF]


Home page
BloodHome page
M. Schroter, H.-H. Feucht, P. Schafer, B. Zollner, R. Laufs, L. Fischer, and B. Knodler
TT Virus Viremia and Liver Transplantation: No Significant Increase of the Prevalence
Blood, December 15, 1998; 92(12): 4877 - 4878.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feucht, H.-H.
Right arrow Articles by Laufs, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feucht, H.-H.
Right arrow Articles by Laufs, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020